ImmuneOncia Therapeutics, Inc. Logo

ImmuneOncia Therapeutics, Inc.

A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.

424870 | KO

Overview

Corporate Details

ISIN(s):
KR7424870004
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 탑실로35번길 25, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ImmuneOncia Therapeutics, Inc. is a clinical-stage, immuno-oncology-centric biopharmaceutical company dedicated to developing cutting-edge immunotherapies for cancer treatment. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in drug development and antibody engineering. ImmuneOncia's pipeline focuses on developing immune checkpoint inhibitors targeting T cells and macrophages. Its portfolio includes IMC-001, its lead candidate, and IMC-002, a fully human anti-CD47 monoclonal antibody for various cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 887.8 KB
2025-05-30 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 43.9 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 102.9 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-12 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 323.5 KB
2025-04-30 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 525.5 KB
2025-04-30 00:00
Prospectus
[기재정정]투자설명서
Korean 3.9 MB
2025-04-28 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.4 MB
2025-04-17 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.2 MB
2025-04-04 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.9 MB
2025-04-02 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.5 MB
2025-03-28 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 397.2 KB
2025-03-14 00:00
Registration Form
증권신고서(지분증권)
Korean 3.1 MB
2024-04-08 00:00
Annual / Quarterly Financial Statement
감사보고서 (2023.12)
Korean 355.7 KB

Automate Your Workflow. Get a real-time feed of all ImmuneOncia Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ImmuneOncia Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ImmuneOncia Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland
IDIA
IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IL DONG PHARMACEUTICAL CO., LTD. Logo
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
ILSUNG IS CO., LTD. Logo
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
ILYANG PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
I-Mab Logo
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
ImageneBio, Inc. Logo
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
IM Cannabis Corp. Logo
International producer of medical-grade cannabis for patients and providers in Israel and Germany.
United States of America
IMCC
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.